Assessment and Comparison of the Efficacy of Methotrexate, Prednisolone, Adalimumab, and Tocilizumab on Multipotency of Mesenchymal Stem Cells

Shuang Liu1*, Takeshi Kiyoi2, Marina Ishida1 and Masaki Mogi1

1 Department of Pharmacology, Ehime University Graduate School of Medicine, Toon, Japan, 2 Department of Advanced Research Support Center, Ehime University, Toon, Japan

Mesenchymal stem cell (MSC)-based articular regeneration might be beneficial for both protecting and rebuilding cartilaginous tissues in the management of rheumatoid arthritis. However, it is unclear how current immunosuppressive strategies influence the multipotency of MSCs. The present study was undertaken to profile the direct effectiveness of major antirheumatic drugs including methotrexate, prednisolone, adalimumab, and tocilizumab on the multipotency of MSCs, with a special focus on chondrogenesis. The inhibitory effects of methotrexate on adipogenesis, osteogenesis, and chondrogenesis were observed to occur in a dose-dependent manner in an in vitro differentiation system. Prednisolone enhanced adipogenesis, but reduced alkaline phosphatase activity in osteoprogenitors and suppressed the formation of chondrospheroids. Adalimumab suppressed alkaline phosphatase activity, while tocilizumab diminished osteogenesis and chondrogenesis of MSCs in vitro. Chondrogenesis of antirheumatic drug-treated MSCs was also evaluated in vivo using a scaffolded spheroid-engrafted murine model. The biologics examined appeared to be relatively safe for cartilaginous formation, but methotrexate and prednisolone exhibited opposing influences on chondrogenesis. Taken together, these results reveal the direct efficacy of major antirheumatic agents on the multipotency of MSCs. Therefore, our findings suggest that optimization of medication protocols is further required for therapeutic approaches involving cartilaginous tissue engineering.

Keywords: mesenchymal stem cells, antirheumatic drugs, chondrogenesis, cartilage regeneration, xenografted model
INTRODUCTION

Rheumatoid arthritis (RA) is characterized by persistent and chronic synovitis in the joint, followed by spontaneous progressive joint destruction, which is evident on X-ray as erosion and progressive narrowing of joint spaces (Sharp et al., 1985). Because joint destruction directly causes joint pain and functional disability, the basic strategy of RA management is altering the systemic immune status to prevent or delay joint destruction. However, after a prolonged period of time, the damage is almost irreversible and very limited options remain other than trying to prevent further destruction of the joint and considering prosthetic replacement arthroplasty. Recently, treatment with disease-modifying antirheumatic drugs (DMARDs) has achieved outstanding results for systemic inflammatory management. However, even when clinical remission is achieved, cartilage damage may continue to progress. With this in mind, approaches to protect against structural damage and repair existing damage have emerged for joint regeneration.

Several therapeutic strategies have been applied for regeneration of joint destruction, such as oral or intravenous medications, treatment of a particular joint with intra-articular injection, and surgical intervention. However, the high proliferative capacity and osteogenic/chondrogenic capabilities of mesenchymal stem cells (MSCs) have catapulted them to the forefront of cell-based therapy for joint-destructive diseases (El-Jawhari et al., 2014; Vizoso et al., 2019). Clinical induction of self-repair capacity via transplantation of multipotent MSCs under strong inhibition of synovitis has been attempted in several previous studies (Ito et al., 2018). In an effort to improve the clinical efficacy of these therapies, techniques for MSC-based tissue engineering have also been developed for the establishment of in vitro–formed spheroids (Zubillaga et al., 2020).

Although the concept of MSC-based joint regeneration has demonstrated promising results and opens new therapeutic possibilities for RA treatment, obstacles for its use are not trivial. For example, the proliferative and chondrogenic potential of RA patient-derived MSCs is reduced compared with normal MSCs. Moreover, RA patient-derived MSCs exhibit decreased cellular telomere length, which may be associated with the patient’s age, background, DMARDs treatment, and altered expression of genes implicated in local adhesion and cell cycle pathways (Kastrinaki et al., 2008). The microenvironment and its interaction with the delivered cell population seem to be crucial for maximizing the therapeutic potential of MSCs. Most patients with RA have been treated and are undergoing continuously treatment with methotrexate, corticosteroids, and/or biologics. However, whether these immunosuppressors can affect the multipotency of transplanted MSCs or their capacity to repair cartilage or bone damage is unknown.

Understanding how individual antirheumatic drugs influence MSCs is necessary for future joint regeneration approaches. The present study was undertaken to screen for direct effects of individual antirheumatic agents on the multipotency of human bone marrow-derived MSCs, using an in vitro differentiation system. With a special focus on chondrogenic differentiative capacity, we also evaluated the in vivo effects of these agents in a murine MSC chondrospheroid-engrafted model.

MATERIALS AND METHODS

Cell Culture and Multipotency Characterization of MSCs

Human cartilage-derived primary MSCs were purchased from the Japanese Collection of Research Bioresources Cell Bank (JCRB, Osaka, Japan). These cells exhibit an expanded lifespan by carrying bmi-1, E6, E7, and hTERT genes, as previously described (Mori et al., 2005). According to instructions from JCRB, MSCs were cultured in preconditioned Poweredge10 Medium (GlycoTechnica, Yokohama, Japan). All experiments were performed with passage 8–13 MSCs.

For observation of MSC multipotency, a Human Mesenchymal Stem Cell Functional Identification Kit (R&D Systems, Minneapolis, MN) was used according to manufacturer’s instructions (Liu et al., 2019). MSCs were differentiated in adipogenic, osteogenic, or chondrogenic conditioned medium, with or without application of the antirheumatic agents methotrexate, prednisolone, adalimumab, and tocilizumab at the indicated concentrations. To evaluate adalimumab, 1 ng/ml (58.82 nM) recombinant human tumor necrosis factor α (TNF-α; PeproTech, Rocky Hill, NJ) was added to each kind of differentiation medium, to establish an inflammatory microenvironment following an established protocol (Zigon-Branc et al., 2018).

Briefly, for adipogenic differentiation, MSCs were cultured in adipogenic differentiation medium containing adipogenic supplements hydrocortisone (0.5 μM), isobutylmethylxanthine, and indomethacin. Seven days later, MSCs were stained with an anti-mouse fatty acid binding protein (mFABP) antibody and counterstained with Hoechst® 33342 (0.5 μg/ml). For fluorescence quantification, image acquisition was performed in an imaging chamber using MetaXpress software (Molecular Devices, Tokyo, Japan; Kiyoi et al., 2018). Thirty-two fields were captured in each well with 100–400 ms exposure times at a magnification of ×200. The integrated intensity of each image was determined under the background-subtracted condition. For functional analysis, lipid droplets that had formed during adipogenic differentiation were stained in fixed cells using an Oil Red O stain kit (Abcam, Cambridge, UK) according to the manufacturer’s instructions.

For osteogenic induction, MSCs were cultured in osteogenic differentiation medium containing dexamethasone (10 nM), ascorbate-phosphate, and β-glycerophosphate for 21 days. Subsequently, surface and functional markers of induced osteocytes were observed. For detection of osteocalcin, cells were labeled using a primary anti-human osteocalcin antibody (R&D Systems, #967801). Image-capturing methods were similar to those described above for adipogenic detection. Functional activity of alkaline phosphatase (ALP) was detected on day 14 in MSCs undergoing osteogenic differentiation using an ALP staining kit (Wako, Tokyo, Japan) according to the manufacturer’s protocol.

For experiments using MSCs spheroids without any scaffold, 2.5 × 10³ MSCs were pelleted in chondrogenic differentiation
medium supplemented with dexamethasone (100 nM), ascorbate-phosphate, proline, pyruvate, recombinant tumor growth factor-β3, insulin, transferrin, selenious acid, bovine serum albumin, and linoleic acid. After 21 days of induction, formed spheroids were sectioned on a cryotome and subjected to aggrecan and CD44 detection. Images were captured using a fluorescence microscope (BZ-9000; Keyence, Osaka, Japan). The volume of formed macromass was quantified by magnetic resonance imaging (MRI) acquired under a three-dimensional (3D) T2-weighted flash sequence protocol using an MRmini SA110 scanner (DS Pharma Biomedical, Osaka, Japan). Coronal and sagittal images were collected and reconstructed to obtain the volume of chondrospheroids.

**Preparation of Chondrospheroids in a 3D Collagen Matrix**

To establish an in vivo chondrogenic drug-screening system, MSCs were differentiated into chondrospheroids on a 3D collagen matrix, which was prepared by immersing a round shape Honeycomb sponge (Koken, Tokyo, Japan) in 50 μl of 2% Atelocollagen Implant (Koken) in a round-bottom 96-well culture plate. The matrix was incubated at 37°C for 1 h, after which 200 μl of prewarmed Poweredby10 Medium was added to the well. The formed matrix was calibrated at 37°C in a humidified atmosphere with 5% CO₂ overnight. MSCs (2.5 × 10⁵) were seeded on plates in chondrogenic differentiation medium and pelleted for chondrogenic differentiation. After 21 days of induction, the formed chondrospheroids were harvested and ready for animal transplantation. To detect chondrogenic makers, formed spheroids were sectioned on a cryotome and subjected to aggrecan and CD44 detection. Images were captured using a fluorescence microscope.

**Establishment of a Xenograft Human RA Model**

Peripheral blood, synovium, articular cartilage, and bone explants were obtained from RA patients who had undergone prosthetic replacement arthroplasty for therapeutic purposes. A murine xenograft RA model was established as previously described (Liu et al., 2017). Briefly, explants of synovium, articular cartilage, and bone obtained from RA patients were grafted onto the muscle at the level of the fourth to sixth lumbar vertebra of male NOD/ShiJic-scid (NOD/SCID) mice aged 6–10 weeks (CLEA Japan, Tokyo, Japan). The same patient-derived peripheral blood monocytes (5 × 10⁶) were resuspended in 100 μl serum and intraperitoneally implanted into mice immediately after the grafting surgical procedure. For MSC-derived chondrospheroid transplantation, predifferentiated spheroids with or without scaffold were implanted on the surface of damaged RA patient-derived cartilage.

Eight weeks after transplantation, mice were sacrificed by cervical dislocation. Implanted tissues were removed from xenograft mice and subjected to fixation, decalcification, and paraffin embedding. The invasion of synovium into cartilage was observed on hematoxylin-stained sections by light microscopy.

**In Vivo Chondrogenic Drug-Screening Model**

Predifferentiated chondrospheroids in a 3D collagen matrix were implanted into NOD/SCID mice. After the subcutaneous tissue was exposed under anesthetic conditions, the oblique external abdominal muscle was scraped with a scalpel until it bled. The chondrospheroids were then implanted. Healthy donor-derived peripheral blood monocytes (5 × 10⁶) were intraperitoneally implanted into mice.

One week after transplantation, antirheumatic regents were continuously subcutaneously infused into mice using implanted osmotic Alzet pumps (DURECT, Cupertino, CA).

For clinical RA treatment, after three oral weekly doses of 2 mg methotrexate, a steady-state plasma concentration of methotrexate (approximately 39.9 ng/ml) is achieved (Inoue and Yuasa, 2014). A steady-state concentration of 3 μg/ml adalimumab is achieved by subcutaneous injection of 40 mg adalimumab every 2 weeks (Ternant et al., 2015). For tocilizumab, the steady-state plasma concentration is 12.3 μg/ml after 8 mg/kg intravenous injection every 2 weeks. Maintenance therapy with a relatively low dose (≤10 mg/day) of prednisolone is used for RA treatment. A dose-calibrated Cmax of 20.7±6.5 μg/L/1 mg for oral administration and 88.3±24 μg/L/1 mg for intravenous injection have been reported (Czock et al., 2005). By referring to the results of these pharmacokinetic studies and previous in vivo studies using murine arthritis models, an equivalent dose for mouse administration based on body surface area was calculated, and an effective dosage range to suppress the systemic inflammatory status with minimum side effects was chosen for each antirheumatic regent (Nair and Jacob, 2016). The doses were 0.25 or 0.5 mg/kg for methotrexate (Singh et al., 2019), 0.1 or 0.2 mg/kg for prednisolone (Hoekens et al., 2011), 0.75 or 1.5 mg/kg for adalimumab (Zafr-Lavie et al., 2017), and 4 or 8 mg/kg for tocilizumab (Thiolat et al., 2014). Mice implanted with saline-filled pumps were used as controls.

Four weeks later, chondrospheroids were explanted from cervically dislocated mice. The volume of formed macromass was quantified by MRI as described above for in vitro studies. Explants were then fixed using 4% paraformaldehyde and subjected to histological analysis. Expression of aggrecan and CD44 in spheroids was detected using an immunofluorescence staining technique.

**Statistical Analysis**

All experiments were designed in a completely randomized multifactorial format. Sample distributions were designed using the Kolmogorov-Smirnov test. Dose-response titrations were fitted by nonlinear regression. Results are expressed as the mean ± standard error of the mean (SEM). The Mann-Whitney U-test was used for nonparametric interclass comparisons and the results are described by the median and interquartile range (difference between 25th and 75th percentiles). The Wilcoxon signed-rank test was used for paired comparisons and the results are expressed as the mean ± standard deviation (SD). P < 0.05 was considered significant. All data were analyzed using Prism 8 (GraphPad Software, La Jolla, CA).
RESULTS

Effects of Antirheumatic Agents on Adipogenic Differentiation Potential of MSCs

Multipotency was evaluated in antirheumatic agent-treated MSCs. Adipocyte protein 2, also called FABP4, was used as a surface marker for differentiated adipocytes. In addition, the formation of lipid droplets, which were stained by Oil Red O, was also observed as a functional marker of differentiated adipocytes.

A typical screening panel for quantification of FABP4 expression in antirheumatic agent-treated MSCs is shown in Figure 1A. A total of 32 panels were obtained, and changes in the average fluorescence intensity of each sample were evaluated. According to the titration curves, FABP4 expression in methotrexate-treated MSCs decreased in a dose-dependent manner with an EC₅₀ of 54.53 nM, whereas prednisolone exhibited a slightly inhibitory effect on FABP4 induction (Figure 1B). Direct application of adalimumab or tocilizumab did not elicit any effect on FABP4 expression in MSCs (Figure 1C). Fluorescence imaging of lipid droplets revealed that prednisolone treatment increased lipid droplet formation (Figures 1D–F). Treatment with >100 nM methotrexate suppressed droplet formation. Both adalimumab and tocilizumab elevated lipid droplet induction at concentrations between 100 ng/ml and 0.1 mg/ml. Taken together, treatment with methotrexate suppressed the adipogenic differentiation potential of MSCs, while prednisolone, adalimumab, and tocilizumab increased lipid droplet induction of MSCs.

Methotrexate, Adalimumab, and Tocilizumab Downregulated Osteogenic Differentiation

Populations of osteogenic cells positive for osteocalcin, bone-specific ALP, or both have been identified (Long et al., 1995). Treatment of MSCs with prednisolone, adalimumab, or tocilizumab did not affect the expression of osteocalcin, a noncollagenous protein of the bone matrix specifically synthesized by osteoblasts that is often used as a marker for the bone formation process (Dirckx et al., 2019) (Figures 2A–C). Treatment with high concentrations of methotrexate (more than 100 nM) slightly downregulated osteocalcin expression in MSCs. Activity of osteoprogenitor-derived ALP, which sensitively indicates new bone formation and osteoblast activity (Abe et al., 2019), exhibited different induction patterns compared with osteocalcin (Figures 2D–F). Methotrexate, adalimumab, and tocilizumab inhibited ALP activity in osteoprogenitors in a dose-dependent manner. EC₅₀ values were 11.03 nM for methotrexate, 607 ng/ml for adalimumab, and 10.64 ng/ml for tocilizumab. In contrast, prednisolone elevated ALP activity at concentrations higher than 1 μM.

Methotrexate, Prednisolone, and Tocilizumab Inhibit Chondrospheroid Formation In Vitro

For chondrospheroid generation, MSC spheroids were cultured in vitro using a high cell-density pellet culture system, which mimics the cellular condensation requirement for embryonic mesenchymal chondrogenesis and provides the physical and biochemical environmental factors conductive to cartilage formation. The spheroids exhibited as compact rounded cell aggregates that maintained their physical structure for the duration of induction and, finally, formed detectable micromasses (Figure 3A). Differentiation levels of the chondrospheroids were assessed by histological staining using the chondrogenic surface marker CD44 and aggrecan, also known as cartilage-specific proteoglycan core protein, as a functional marker of chondrogenesis. Chondrospheroids developed a multilayered matrix-rich morphology (Figure 1B). CD44-positive cellular aggregates and an aggrecan-rich extracellular matrix were observed, regardless of whether antirheumatic agents had been applied.

As an indicator of cell proliferation, matrix deposition, and intercellular space volume, the volume of chondrospheroids was quantified (Martinez et al., 2008) (Figures 3C–F). Compared with nontreated chondrospheroid, volumes were decreased to 34.84% in 100 nM methotrexate-treated chondrospheroids (P = 0.023) and 33.63% in 1 μM methotrexate-treated chondrospheroids (P < 0.001). Significantly decreased volumes were also observed in prednisolone-treated (1 μM) and tocilizumab-treated (1 mg/ml) chondrospheroids. Taken together, methotrexate, prednisolone, tocilizumab exhibited greater or lesser inhibitory effects on in vitro chondrospheroid formation.

Profiling the Effects of Antirheumatic Agents on Chondrogenesis of MSCs In Vivo

With the aim of evaluating the effects of antirheumatic agents on MSC-based joint regeneration, a chimeric human-mouse model was established for in vivo drug screening. To increase the viability and adhesion of chondrospheroids prepared for in vivo transplantation, a porous 3D collagen matrix was used as a scaffold. Chondrospheroids with and without scaffold were implanted into NOD/SCID mice preengrafted with healthy donor-derived PBMCs. Four weeks later, a firm cartilaginous mass was formed by chondrospheroids with scaffolds, while a softer and more unstable cartilaginous mass was formed by chondrospheroids without scaffolds (Figure 4A). Cartilaginous particles were then explanted and histologically characterized (Figure 4B). Cartilaginous particles with and without scaffolds formed a densely layered structure with aggrecan-rich extracellular matrix. Compared with chondrospheroids before engrafting, CD44 expression, which was confirmed on cell surfaces in chondrospheroids before engrafting, became undetectable.

The capability of MSCs-derived spheroids for cartilage repair was examined in a xenografted RA model. In this model, RA patient-derived synovial tissue, bone, and articular cartilage were xenografted into NOD/SCID mice. According to the results of histological evaluation, with an inflammatory microenvironment supported by autologous PBMC engraftment, the patient-derived synovium invaded into implanted cartilage and even bone tissue, whereas synovial invasion was markedly inhibited by chondrospheroid transplantation (Figure 4C). Especially in chondrospheroids of scaffold-transplanted mice, the regeneration of cartilage tissue and repair of damaged cartilage surface were observed. These results indicated that MSC-derived chondrospheroids can survive in a xenografted murine model and are capable of repairing articular...
cartilage defects. Thus, chondrospheroids of scaffold-implanted mice are useful for further drug efficacy assessments.

After subcutaneous delivery of antirheumatic agents, the volumes of explanted cartilaginous mass were quantified (Figures 4D–G). Compared with untreated mice, methotrexate (10 mg/kg) significantly decreased cartilaginous mass formation ($P = 0.041$). Interestingly, the inhibitory effect of prednisolone was only observed in the 5 mg/kg prednisolone-treated mice ($P = 0.009$), but not 10 mg/kg prednisolone-treated mice. The biologics did not show any influence on cartilaginous mass formation.

**DISCUSSION**

The management of rheumatology faces an enormous challenge: the largely irreversible nature and joint damage and erosion. Current immunosuppressive agents achieve neither restoration of joint architecture nor reversal of damage (Kerrigan and McInnes, 2020). Although MSCs might be beneficial for both protecting and rebuilding cartilaginous tissues, how current immunosuppressive strategies influence the multipotency of MSCs is largely unknown. The present study was undertaken to profile the direct effectiveness of major antirheumatic drugs, including glucocorticoids, conventional synthetic DMARDs, and biologics, on the multipotency of MSCs. By acknowledging pharmacological, metabolic, and cellular mechanisms, we attempt to provide insights into the contribution of these drugs with regard to healing capacity and MSC-based tissue engineering.

As a first-line drug for the treatment of RA, nearly all patients with inflammatory arthritis are currently given methotrexate in the absence of contraindications (Cronstein and Aune, 2020). If patients do not respond, they are prescribed other immunosuppressive therapies, such
glucocorticoids or biologics, usually in combination with methotrexate. Methotrexate functionally inhibits the de novo synthesis of purines and pyrimidines that is required for DNA and RNA synthesis, as well as cell proliferation. In our study, in vitro treatment with methotrexate significantly suppressed the multilineage (adipogenic, osteogenic, and chondrogenic) potencies of MSCs, consistent with the results of a previous study (Beane et al., 2016). Undifferentiated stem cells exhibited resistance to methotrexate; even concentrations of methotrexate as high as 50 μM did not affect cell proliferation. However, once stem cells were placed in a differentiation-inducing environment, their tolerance level was significantly decreased, as a 5- to 10-fold higher susceptibility was observed in nonstem status cells. These changes might result from a dihydrofolate reductase-mediated mechanism.

In addition to direct application in vitro, continuous subcutaneous infusion of methotrexate also markedly inhibited the formation of cartilaginous masses in MSC spheroid-grafted mice. Compared with oral administration, enhanced bioavailability can be achieved by constant long-term subcutaneous delivery, which can prolong the potency of polyglutamated methotrexate (the active form of methotrexate) in tissues (Kremer et al., 1986; Herman et al., 1989). Although better responses to methotrexate or other antirheumatic drugs can be achieved by parenteral administration, this route
imparts a higher risk of effects on the multipotency of MSCs, which should be considered when protecting and rebuilding cartilaginous tissues. In addition, whether the chondrogenic potency of MSCs can be restored by concomitant administration of folic acid or folinic acid should be examined to optimize cartilage tissue engineering for RA treatment.

In individuals with RA, oral glucocorticoid usage continues to be widespread, although it is potentially declining (Hardy et al., 2020). As glucocorticoids are required for both adipogenesis and osteoblastogenesis, their influence on the multipotency of MSCs should be evaluated. In *in vitro* culture systems, dexamethasone is important for the initiation of adipogenic differentiation by activating C/EBPδ expression through binding to intracellular glucocorticoid receptor (Chen et al., 2016). For osteoblastogenic differentiation, dexamethasone promotes cell proliferation, resulting in the induction of ALP activity. These hypotheses were confirmed by the results of our *in vitro* assessment, including the enhancement of lipid drop formation and elevation of ALP activity in prednisolone-treated MSCs. However, exposure to supraphysiological levels of glucocorticoids could be associated with reduced bone mineral density, impaired bone quality, and increased risk of fracture. Shifting the balance from osteoblastogenesis to adipogenesis has been widely accepted as one of the mechanisms by which glucocorticoids diminish osteoblast differentiation (Hartmann et al., 2016).

Interestingly, during chondrogenic differentiation, detrimental effects were observed in 1 μM prednisolone-treated MSCs and 0.1 mg/kg prednisolone-treated mice. However, this inhibitory effect disappeared in 0.2 mg/kg prednisolone-treated mice. The impact of glucocorticoid exposure on chondrogenesis of MSCs seems ambiguous with the combination of this apparently contradictory evidence. First, dexamethasone is used in conjunction with transforming growth factor beta-1 (TGF-β1) in our chondrogenic differentiation system for the induction of differentiation of cartilage derived-MSCs. A previous study reported that the influence of steroids is dependent on the source of cells (tissue of origin and its microenvironment).
In this study, dexamethasone enhanced TGF-β1-induced chondrogenesis in bone marrow-derived MSCs, but significantly inhibited TGF-β1-induced synovium-derived aggregates. The results of our in vitro assessment revealed that exposure to prednisolone suppressed the chondrogenic capacity of cartilage-derived MSCs. Second, at present, we can offer no plausible explanation for the variable effects of prednisolone on in vivo cartilage-like tissue formation of MSCs. Corticoids can reportedly cause cartilage hypertrophy during MSCs differentiation (Kovermann et al., 2019). By detecting a genetic hypertrophic marker, the ratio of COL2A1/COL10A1, researchers found that exposure to dexamethasone led to hypertrophic chondrogenesis, which is associated with a temporary cartilage template that will remodel into bone. Based on these results, they suggested that to obtain a more stable chondrogenic induction, the availability of glucocorticoids should be reappraised. We evaluated the chondrogenic capability of chondrospheroids by assessing the volume of in vivo formed micromass and quality of cartilaginous mass, as evaluated by aggrecan expression. However, no hypertrophic marker was
Dramatic functional compensation of epidermal FABP (FABP5), which is also expressed in adipocytes, may provide an explanation for the disconnect between the FABP4 differentiation readout and lipid droplet formation. Because FABP5 compensates for the function of FABP4 deficiency in overall metabolic homeostasis, the antirheumatic agent-induced inhibitory effects may have been compensated by FABP5 (Furuhashi and Hotamisligil, 2008). A study to dissect the expression balance and address the potential adipogenic effects of these FABP isoforms may provide further understanding of the role of MSC adipogenic potency in articular homeostasis maintenance.

In summary, we profiled the influence of major antirheumatic drugs on the multipotency of human cartilage–derived MSCs that are an important cell source for tissue renewal and regeneration. While biologics exhibited relatively little effects, small molecular compounds, such as methotrexate and prednisolone, somewhat affected the osteogenesis and chondrogenesis of MSCs. In clinical management of RA, glucocorticoids and methotrexate are generally considered to be a part of the initial treatment strategy, and therapy using these drugs is often started as soon as the diagnosis of RA is made. Additionally, in patients responding insufficiently to synthetic chemical compounds, biological agents are always commenced with methotrexate. While expecting remarkable immunomodulatory efficacy, the opposite effects on self-repair should always be considered by rheumatologists, especially in the case of using a high-dose of methotrexate or a combination of glucocorticoids and methotrexate for long-term treatment. Thus, optimization of medication protocols is required for treatment approaches aimed at protecting and rebuilding cartilaginous tissues. Notably, the most common treatment strategies rely on a combination of conventional synthetic DMARDs, targeted synthetic DMARDS, and biological DMRDS instead of single agent administration. The present profile is not sufficient to justify cross-strategy management of medications and tissue engineering for RA therapy and additional investigations are required to provide a complete perspective of antirheumatic drugs in the regenerative field.

**CONCLUSION**

According to the results of the present study, biologics appear to be relatively safe for cartilaginous formation, although methotrexate and prednisolone exhibited opposing influences. Therefore, our findings suggest that optimizing medication protocols is required for therapeutic approaches involving cartilaginous tissue engineering.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.
ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of Ehime University School of Medicine. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by University Committee for Animal Research, Ehime University.

AUTHOR CONTRIBUTIONS

SL: conceptualization, methodology, formal analysis, writing—original draft, funding acquisition. TK: methodology, investigation, writing, review and editing, validation. MI: investigation. MM: supervision, project administration.

REFERENCES

Abe, Y., Chiba, M., Yaklai, S., Pechayco, R. S., Suzuki, H., and Takahashi, T. (2019). Increase in bone metabolic markers and circulating osteoblast-lineage cells after orthognathic surgery. Sci. Rep. 9, 20106. doi: 10.1038/s41598-019-56484-x

Beane, O. S., Darling, L. E., Fonseca, V. C., and Darling, E. M. (2016). Disparate Response to Methotrexate in Stem Versus Non-Stem Cells. Stem Cell Rev. Rep., 12, 340–351. doi: 10.1007/s12015-016-9645-9

Chen, Q., Shou, P., Zheng, C., Jiang, M., Cao, G., Yang, Q., et al. (2016). Fate decision of mesenchymal stem cells: adipocytes or osteoblasts? Cell Death Differ. 23, 1128–1139. doi: 10.1038/cdd.2015.168

Cronstein, B. N., and Aune, T. M. (2020). Methotrexate and its mechanisms of action in inflammatory arthritis. Nat. Rev. Rheumatol. 16, 145–154. doi: 10.1038/s41584-020-0373-9

Czock, D., Keller, F., Rasche, F. M., and Häusler, U. (2005). Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin. Pharmacokinet. 44, 61–98. doi: 10.2165/00003088-200544010-00003

Dirckx, N., Moorer, M. C., Clemens, T. L., and Biddle, R. C. (2019). The role of osteoblasts in energy homeostasis. Nat. Rev. Endocrinol. 15, 651–665. doi: 10.1038/s41574-019-0246-y

El-Jawhari, J. J., El-Sherbiny, Y. M., Jones, E. A., and McGonagle, D. (2014). Mesenchymal stem cells, autoimmunity and rheumatoid arthritis. Qjm 107, 505–514. doi: 10.1093/qjmed/hcu033

Furuhashi, M., and Hotamisligil, G. S. (2008). Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat. Rev. Drug Discovery 7, 489–503. doi: 10.1038/nrd2589

Golub, E. E., Harrison, G., Taylor, A. G., Camper, S., and Shapiro, I. M. (1992). The role of alkaline phosphatase in cartilage mineralization. Bone Miner. 17, 273–278. doi: 10.1016/0169-6009(92)90705-8

Hardy, R. S., Raza, K., and Cooper, M. S. (2020). Therapeutic glucocorticoids: mechanisms of action in rheumatic diseases. Nat. Rev. Rheumatol. 16, 133–144. doi: 10.1038/s41584-020-0371-y

Hartmann, K., Koenen, M., Schauer, S., Wittig-Blaich, S., Ahmad, M., Baschant, U., et al. (2016). Molecular Actions of Glucocorticoids in Cartilage and Bone During Health, Disease, and Steroid Therapy. Physiol. Rev. 96, 409–447. doi: 10.1152/physrev.00011.2015

Herman, R. A., Veng-Pedersen, P., Hoffmann, J., Koehnke, R., and Furst, D. E. (1989). Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J. Pharm. Sci. 78, 165–171. doi: 10.1002/jps.2600780219

Hofkens, W., van den Hoven, J. M., Pesman, G. J., Nabbe, K. C., Sweep, F. C., Storm, G., et al. (2011). Safety of glucocorticoids can be improved by lower yet still effective dosages of liposomal steroid formulations in murine antigen-induced arthritis: comparison of prednisolone with budesonide. Int. J. Pharm. 416, 493–498. doi: 10.1016/j.ijpharm.2011.02.062

Inoue, K., and Yuasa, H. (2014). Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug Metab. Pharmacokinet. 29, 12–19. doi: 10.2123/dmp.k.DMPK-13-RV-19

FUNDING

SL was supported by the Japan Society for the Promotion of Science (JSPS) and Grants-in-Aid for Scientific Research (KAKENHI) grant number 18K08389.

ACKNOWLEDGMENTS

We are grateful to Dr. Yasuaki Okuda and Dr. Eijiro Adachi from the Dohgo Spa Hospital, Center for Rheumatoid Diseases, for providing blood and tissue samples form patients with RA. We thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.
affecting their neurogenic potential. *Mol. Cell Biol.* 25, 5183–5195. doi: 10.1128/MCB.25.12.5183-5195.2005

Nair, A. B., and Jacob, S. (2016). A simple practice guide for dose conversion between animals and human. *J. Basic Clin. Pharm.* 7, 27–31. doi: 10.4103/0976-0105.177703

Sharp, J. T., Young, D. Y., Bluhm, G. B., Brook, A., Brower, A. C., Corbett, M., et al. (1985). How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? *Arthritis Rheumatol.* 28, 1326–1335. doi: 10.1002/art.1780281203

Shintani, N., and Hunziker, E. B. (2011). Differential effects of dexamethasone on the chondrogenesis of mesenchymal stromal cells: influence of microenvironment, tissue origin and growth factor. *Eur. Cell Mater.* 22, 302–319; discussion 319-320. doi: 10.22203/eCM.v022a23

Singh, R. K., van Haandel, L., Kiptoo, P., Becker, M. L., Siahaan, T. J., and Funk, R. S. (2019). Methotrexate disposition, anti-folate activity and efficacy in the collagen-induced arthritis mouse model. *Eur. J. Pharmacol.* 853, 264–274. doi: 10.1016/j.ejphar.2019.03.052

Ternant, D., Bejan-Angoulvant, T., Passot, C., Mulleman, D., and Paintaud, G. (2015). Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis. *Clin. Pharmacokinet.* 54, 1107–1123. doi: 10.1007/s40262-015-0296-9

Thiolat, A., Semerano, L., Pers, Y. M., Biton, J., Lemeiter, D., Portales, P., et al. (2014). Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis. *Arthritis Rheumatol.* 66, 273–283. doi: 10.1002/art.38246

Vizoso, F. J., Eiro, N., Costa, L., Esparza, P., Landin, M., Diaz-Rodriguez, P., et al. (2019). Mesenchymal Stem Cells in Homeostasis and Systemic Diseases: Hypothesis, Evidences, and Therapeutic Opportunities. *Int. J. Mol. Sci.* 31, 20. doi: 10.3390/ijms2013737

Wang, W., Wang, L., Gulkos, P. S., and Zhu, J. (2019). Computational deconvolution of synovial tissue cellular composition: presence of adipocytes in synovial tissue decreased during arthritis pathogenesis and progression. *Physiol. Genomics* 51, 241–253. doi: 10.1152/physigénomics.00009.2019

Xie, Z., Tang, S., Ye, G., Wang, P., Li, J., Liu, W., et al. (2018). Interleukin-6/interleukin-6 receptor complex promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells. *Stem Cell Res. Ther.* 9, 13. doi: 10.1186/s13287-017-0766-0

Zafir-Lavie, I., Miari, R., Sherbo, S., Krispel, S., Tal, O., Liran, A., et al. (2017). Sustained secretion of anti-tumor necrosis factor α monoclonal antibody from ex vivo genetically engineered dermal tissue demonstrates therapeutic activity in mouse model of rheumatoid arthritis. *J. Gene Med.* 19, e2965. doi: 10.1002/jgm.2965

Žigon-Branc, S., Barlič, A., Knežević, M., Jeras, M., and Vunjak-Novakovic, G. (2018). Testing the potency of anti-TNF-α and anti-IL-1β drugs using spheroid cultures of human osteoarthritic chondrocytes and donormatched chondrogenically differentiated mesenchymal stem cells. *Biotechnol. Prog.* 34, 1045–1058. doi: 10.1002/btpr.2629

Zubillaga, V., Alonso-Varona, A., Fernandez, S. C. M., Salberria, A. M., and Palomares, T. (2020). Adipose-Derived Mesenchymal Stem Cell Chondroprogenitors Cultured in Hypoxia and a 3D Porous Chitosan/Chitin Nanocrystal Scaffold as a Platform for Cartilage Tissue Engineering. *Int. J. Mol. Sci.* 3, 21. doi: 10.3390/ijms21031004

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Liu, Kiyoi, Ishida and Mogi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.